Compare Ascendis Pharma A/S (ASND) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs C.H. Robinson Worldwide, Inc. — how do they compare? Ascendis Pharma A/S trades at $263.72 (market cap $17.74B), while C.H. Robinson Worldwide, Inc. trades at $196.97 (market cap $22.81B). The key difference: C.H. Robinson Worldwide, Inc. is the larger of the two by market cap, and C.H. Robinson Worldwide, Inc. pays a 1.3% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | CHRW | |
|---|---|---|
Market Cap | $17.74B | $22.81B |
Sector | Health | Industrials |
52-Week High | $277.18 | $200.59 |
52-Week Low | $163.32 | $96.82 |
Enterprise Value | $18.11B | $24.29B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CHRW trades at $193.5, up 0.38% today, with a bullish technical signal from moving averages and a consensus analyst price target of $199.25. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.35 surpassing the $1.23 estimate. The company maintains strong profitability with a 34.84% ROE and recently acquired DeSpir Logistics to enhance high-value cargo capabilities, signaling strategic growth initiatives.
The outlook is positive, supported by earnings momentum and operational efficiency, but risks include a high P/E ratio of 39.17 suggesting premium valuation, exposure to freight market cyclicality, and competitive pressures in the logistics sector. Upside potential hinges on continued execution and industry recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
